Content about Specialty pharmacy

February 23, 2012

In November 2011, The Drug Store News Group/Specialty Pharmacy magazine hosted in New York an exclusive executive round-table discussion of leading specialty pharmacy providers. Guest moderator and veteran pharmacy executive Dave Fong and the panel examined a range of topics, including channel management strategies, accountable care organizations and the importance of technology.

Click below to download the complete PDF of the 2011 Specialty Pharmacy Roundtable.

April 22, 2014

Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

INDIANAPOLIS — Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, Cyramza becomes the first FDA-approved treatment for patients in this setting.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

ZURICH — Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports. Novartis exchanged its vaccine business with GlaxoSmithKline in a deal valued at $7.1 billion for GSK's oncology portfolio (at a cost of $14.5 billion) and divested its animal health unit to Ely Lilly for approximately $5.4 billion. 

April 21, 2014

Boehringer Ingelheim Pharmaceuticals has announced that the Food and Drug Administration and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has announced that the Food and Drug Administration and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia. Volasertib currently is being evaluated in a Phase III clinical trial for the treatment of patients ages 65 years or older with previously untreated AML who are ineligible for intensive remission induction therapy. 

Volasertib has not been approved by the FDA or EC regulatory authorities; its safety and efficacy have not been established.

April 21, 2014

GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.

LONDON — GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate.

April 14, 2014

AssistRx last week introduced a new technology that simplifies the prescribing of specialty therapies while streamlining communications between prescribers, pharmacies, patients and manufacturers. It’s smart technology that can lead to patients receiving specialty medications weeks earlier than ever before, the company claimed.

ORLANDO, Fla. — AssistRx last week introduced a new technology that simplifies the prescribing of specialty therapies while streamlining communications between prescribers, pharmacies, patients and manufacturers. It’s smart technology that can lead to patients receiving specialty medications weeks earlier than ever before, the company claimed.

April 14, 2014

The Biotechnology Industry Organization and the Delaware BioScience Association last week commended the Delaware State Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

WASHINGTON — The Biotechnology Industry Organization and the Delaware BioScience Association last week commended the Delaware State Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

The Delaware State Senate passed Senate Substitute 1 for Senate Bill 118. 

April 8, 2014

Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.

FLINT, Mich. — Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). 

Otezla was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. 

April 8, 2014

Rite Aid on Tuesday announced it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accreditation organization that establishes quality standards for the healthcare industry.

CAMP HILL, Pa. — Rite Aid on Tuesday announced it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accreditation organization that establishes quality standards for the healthcare industry. 

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

DUBLIN — Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, the transaction currently is expected to be completed in the third calendar-quarter of 2014.

April 7, 2014

OncologyRx Care Advantage, McKesson Specialty Health’s oral oncology products specialty pharmacy, on Monday announced that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.

THE WOODLANDS, Texas — OncologyRx Care Advantage, McKesson Specialty Health’s oral oncology products specialty pharmacy, on Monday announced that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.

“Without this financial support, most of these patients simply would not be able to obtain the medication they need to continue treatment," said Larry Whisenant, director of Specialty Pharmacy Operations, OncologyRx Care Advantage. 

April 7, 2014

Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion.

MUMBAI, India — Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion. 

The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India, Sun Pharma stated. The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and a significant platform of specialty and generic products marketed globally, including 629 abbreviated new drug applications. 

April 3, 2014

Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis.

LAKE MARY, Fla. — Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis. Axium is one of a limited number of specialty pharmacies selected by drug manufacturer Celgene to dispense Otezla, which was approved by the Food and Drug Administration on March 21.

March 31, 2014

Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug.

PHOENIX — Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug. 

At this time, Avella is one of a select number of pharmacies that are contracted by Celgene, the drug manufacturer, to dispense the product at launch.

March 28, 2014

Rebecca Shanahan, CEO of Avella Specialty Pharmacy, will be the keynote speaker at the Academy of Managed Care Pharmacy’s Specialty Pharmacy Conference 2014, Avella announced Wednesday.

PHOENIX — Rebecca Shanahan, CEO of Avella Specialty Pharmacy, will be the keynote speaker at the Academy of Managed Care Pharmacy’s Specialty Pharmacy Conference 2014, Avella announced Wednesday. 

March 28, 2014

Lupin on Thursday announced the acquisition of 100% equity stake in Laboratorios Grin, subject to certain closing conditions.

BALTIMORE — Lupin on Thursday announced the acquisition of 100% equity stake in Laboratorios Grin, subject to certain closing conditions. The acquisition marks Lupin's foray into the high-growth Mexican and the larger Latin American pharmaceuticals market. Mexico is one of the fastest-growing pharmaceutical markets in the world, valued at more than $13.5 billion and growing at 9% to 10% annually.

March 27, 2014

Indiana Governor Mike Pence earlier this week signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines, according to published reports.

INDIANAPOLIS — Indiana Governor Mike Pence earlier this week signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines, according to published reports. 

The bill allows a pharmacist to substitute an interchangeable biosimilar product for a prescribed biological product if certain conditions are met. It requires the board of pharmacy to maintain a website that lists the biosimilar biological products that are determined to be interchangeable. 

The specific conditions include: 

March 27, 2014

PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014.

PITTSBURGH — PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014. 

As an ADAP provider, PANTHERx Specialty will help to facilitate no-cost access to essential medications for low-income, uninsured and under-insured residents of South Carolina, utilizing a combination of state and federal funds. The South Carolina ADAP serves approximately 3,200 enrollees monthly.

March 25, 2014

Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research.

ARLINGTON, Va. — Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research. 

According to the report, independent clinics commanded 59% of distributor sales in 2012, down from 66% in 2011. Sales to hospitals and specialty pharmacies, on the other hand, increased by 6% (combined) to comprise an average of 26% of specialty distributors’ sales. 

March 24, 2014

Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.

SUMMIT, N.J. — Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. Otezla is the only FDA-approved oral treatment for psoriatic arthritis.

March 21, 2014

Advanced Care Scripts, a division of Omnicare Specialty Care Group, on Friday announced that it has been awarded specialty pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accrediting organization.

ORLANDO, Fla. — Advanced Care Scripts, a division of Omnicare Specialty Care Group, on Friday announced that it has been awarded specialty pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accrediting organization. URAC offers one of the only third-party, voluntary accreditation programs of this scope for the pharmacy benefit management and prescription services industries.  

March 21, 2014

Armada's Specialty Pharmacy Summit and Expo returns to the Wynn Las Vegas May 5 to 9, to celebrate a decade of leadership in the specialty pharmacy industry.

FLORHAM PARK, N.J. — Armada's Specialty Pharmacy Summit and Expo returns to the Wynn Las Vegas May 5 to 9 to celebrate a decade of leadership in the specialty pharmacy industry. To date, executives and key decision-makers from more than 700 companies have registered for this year's Summit, the company announced Friday.

March 21, 2014

Rx Response earlier this week established a new membership structure that will enable individual companies in the bio-pharmaceutical supply chain to become direct members.

WASHINGTON — Rx Response earlier this week established a new membership structure that will enable individual companies in the bio-pharmaceutical supply chain to become direct members.

March 20, 2014

The Food and Drug Administration announced the approval of Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is caused by Leishmania, a parasite transmitted to humans through sand fly bites.

SILVER SPRING, Md. — The Food and Drug Administration announced the approval of Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is caused by Leishmania, a parasite transmitted to humans through sand fly bites. It's the first FDA-approved drug to treat cutaneous or mucosal leishmaniasis.

March 20, 2014

Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.

DUBLIN — Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.